Interview with Odnir Finotti, Executive President, Pró Genéricos
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Address: Rua Alvorada, 1280
CEP : 04550-004
Rua Alvorada, 1280 CEP : 04550-004 São Paulo – SP,Brazil
Tel: (11) 3897-9767
Web: http://www.progenericos.org.br/
Founded in January 2001, the Brazilian Association of Generic Drugs – Pró Genéricos brings together leading laboratories working in the production and marketing generic drugs in the country.
Pró Genéricos is a nonprofit entity whose main mission is to contribute to the improvement of access to medicines in Brazil through the consolidation and expansion of the generics market.
Together, the members of the Pro Generic constitutes around 90% of sales in the generics business in the country. Pro Generic connects various sectors of society, institutions of public and private channels with the actions of its members, giving substance to public debate on issues relevant to the health sector and the development of the pharmaceutical industry in the country .
Since September 2005, Pró Genéricos has been part of the Generic IGPA (International Generic Pharmaceutical Alliance), as an observer. Founded in March 1997, the IGPA is an international organization that seeks to ensure consumer access to medicines that meet quality and economy.
Industry Association.
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
See our Cookie Privacy Policy Here
